UNSPSC 51422319: Fluperolone

This classification denotes a fluprednisolone analog and pregnadienetriol, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S33056JLS5. European Medicines Agency schedules Fluperolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07729MIG. Fluperolone generally arises in the molecular formula C22H29FO5.

The term FLUPEROLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) FLUPEROLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fluperolone under HS 29372200 and SITC 54153. As of Q4 2014, FLUPEROLONE remains the US FDA Preferred Term for this commodity. SMILES: CC(C(=O)C1(CCC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)O)O.

UNSPSC 51422319 Fluperolone (Commodity) represents pharmaceutical products procured by state and local health and emergency-management agencies, though recent state and local solicitations under this code show misalignment between the nominal commodity and actual purchasing activity. The single recent opportunity in the dataset is Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, which seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually—opioid-reversal medication and harm-reduction equipment, not fluperolone. The procurement is structured as a competitive invitation for bid with a response deadline of July 26, 2026, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must include all shipping and delivery costs in their proposals, submit bids electronically through the county's e-Procurement Portal, hold workers' compensation and commercial general liability insurance, and comply with E-Verify and drug-free workplace requirements. The initial contract term is two years with a one-year renewal option and a three-month probationary period allowing termination without cause.

The code shows minimal recent state and local activity relevant to its stated pharmaceutical scope. Geographic and issuing-body characterization rests on a single opportunity from a Florida county health department. The procurement appears to be potentially funded through FEMA, introducing compliance obligations under federal environmental statutes. Absent additional opportunities in the dataset, the code does not present a clear procurement signal for business development targeting fluperolone or related pharmaceutical commodities at the state and local level; the single posted opportunity reflects demand for naloxone and drug-disposal systems rather than the code's nominal product line.